Please assess the completion status of the following clinical trial:

Trial Title: A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older;~* isolated traumatic injury to upper or lower extremity;~* alert and oriented to name, date, place; patient has a numeric pain score of 5 or higher;~* speaks English as their primary language;~* female patients are on birth control, menopausal, or are sterile (hysterectomy, tubal ligation)~Exclusion Criteria:~* injury isolated to a finger or toe;~* previous nasal or sinus surgery; chronic nasal problem;~* acute nasal problem (ie epistaxis, upper respiratory infection, sinusitis);~* pregnant; prisoner; allergy to sufentanil, fentanyl, or alfentanil; history of analgesic abuse or dependency;~* presence of other painful injuries; systolic Blood Pressure less than 100 mm Hg;~* patient seems or is confused or has a head injury; room air oxygenation less than 95%;~* patient has chronic obstructive pulmonary disease, severe asthma, oxygen-dependent pulmonary disease;~* impaired hepatic or renal function (obtained clinically or by history);~* weight more than 230 lbs (100 kg);~* alcohol or drug intoxication (per patient admission or clinical assessment of physician);~* elderly (\> 70 years)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal sufentanil, pain relief (Type: EXPERIMENTAL): Intranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period

Based on this trial design, predict the completion outcome and termination type (if applicable).